Andrew is an experienced oncology professional with over 30 years of proven results across the entire spectrum of pharmaceutical drug development including clinical, regulatory, and marketing functions. Andrew graduated with a B.S. in Pharmacy from the University of Maryland. He then gained clinical research experience at the National Cancer Institute and Penn State Medical Center. During a successful career at Eli Lilly, he excelled in positions with medical information, market research, regulatory and medical affairs, as well as clinical development. After retiring from Eli Lilly, he initiated a successful second career in a leadership role at Verastem Oncology followed by a career at OncXerna Therapeutics. He has experience in multiple diverse areas and exposure to compounds at all phases of development from preclinical to late-stage clinical development.
Current role